Appointment of Joint Broker

19^th Sep 2016

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of N+1 Singer as Joint Broker to the Company, alongside Panmure Gordon, with immediate effect. Panmure Gordon remains Nominated Adviser to the Company.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Peter Steel Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF's DiaSpect Tm hemoglobin analyzer supports anemia study in resource limited West Africa

Battery powered point-of-care analyzer demonstrated as ideal for operation in extreme temperatures and remote areas.

EKF at MEDLAB - Singapore 2019

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most established healthcare distributor

4th Annual AIDF Africa Summit

Meet EKF Diagnostics at AIDF 2019 in Nairobi, Kenya this February.

MEDLAB Middle East - Feb 2019

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.